Several other equities research analysts have also recently issued reports on the stock. UBS Group cut shares of Syneos Health from a buy rating to a neutral rating and set a $55.00 price objective on the stock. in a research report on Tuesday, March 19th. Robert W. Baird set a $60.00 price objective on shares of Syneos Health and gave the company a buy rating in a research report on Tuesday, January 8th. Zacks Investment Research cut shares of Syneos Health from a buy rating to a hold rating in a research report on Saturday, January 5th. SunTrust Banks reduced their price objective on shares of Syneos Health to $55.00 and set a buy rating on the stock in a research report on Wednesday, December 19th. Finally, Barclays reduced their price objective on shares of Syneos Health from $51.00 to $45.00 and set an equal weight rating on the stock in a research report on Thursday, January 3rd. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $52.70.
Syneos Health stock opened at $49.89 on Friday. The company has a market cap of $5.19 billion, a PE ratio of 19.04, a P/E/G ratio of 1.43 and a beta of 1.45. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.97. Syneos Health has a 1 year low of $36.26 and a 1 year high of $56.34.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Monday, March 18th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.16. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Syneos Health had a net margin of 0.55% and a return on equity of 9.60%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 earnings per share. As a group, analysts anticipate that Syneos Health will post 2.72 earnings per share for the current fiscal year.
In related news, CEO Alistair Macdonald sold 8,143 shares of the business’s stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $53.00, for a total value of $431,579.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.57% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. NumerixS Investment Technologies Inc bought a new stake in Syneos Health in the fourth quarter worth $57,000. Boston Advisors LLC bought a new position in Syneos Health during the fourth quarter valued at $2,121,000. Oregon Public Employees Retirement Fund increased its position in Syneos Health by 9.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 24,127 shares of the company’s stock valued at $949,000 after acquiring an additional 2,085 shares during the last quarter. Vanguard Group Inc increased its position in Syneos Health by 9.9% during the third quarter. Vanguard Group Inc now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after acquiring an additional 624,991 shares during the last quarter. Finally, BB&T Corp increased its position in Syneos Health by 14.2% during the fourth quarter. BB&T Corp now owns 7,538 shares of the company’s stock valued at $296,000 after acquiring an additional 936 shares during the last quarter.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Recommended Story: Put Option Volume
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.